Stockscreener 앱 받기
50.46
0.02%
0.010
시간 외 거래:
50.46
전일 마감가:
$50.45
열려 있는:
$50.73
하루 거래량:
1.06M
Relative Volume:
0.69
시가총액:
$4.02B
수익:
-
순이익/손실:
$-269.44M
주가수익비율:
-13.46
EPS:
-3.75
순현금흐름:
$-262.63M
1주 성능:
+4.32%
1개월 성능:
+0.18%
6개월 성능:
-6.92%
1년 성능:
+102.41%
1일 변동 폭
$49.44
$51.39
1주일 범위
$48.07
$53.02
52주 변동 폭
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
명칭
Akero Therapeutics Inc
전화
650-487-6488
주소
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
AKRO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
50.46 | 4.21B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-04 | 개시 | TD Cowen | Buy |
| 2025-01-30 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-01-27 | 재확인 | H.C. Wainwright | Buy |
| 2024-11-18 | 개시 | Citigroup | Buy |
| 2024-04-22 | 재개 | BofA Securities | Neutral |
| 2023-09-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-08-28 | 개시 | UBS | Buy |
| 2023-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-10-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-02-26 | 개시 | Guggenheim | Buy |
| 2020-09-10 | 개시 | Morgan Stanley | Overweight |
| 2020-07-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2020-07-01 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-02 | 개시 | H.C. Wainwright | Buy |
| 2020-02-10 | 개시 | Canaccord Genuity | Buy |
| 2019-07-15 | 개시 | Evercore ISI | Outperform |
| 2019-07-15 | 개시 | JP Morgan | Overweight |
| 2019-07-15 | 개시 | Jefferies | Buy |
| 2019-07-15 | 개시 | ROTH Capital | Buy |
모두보기
Akero Therapeutics Inc 주식(AKRO)의 최신 뉴스
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 12,500 Shares of Stock - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
Akero Therapeutics Inc. Hits Price Floor — Bounce IncomingAccurate Technical Trend Reversal Picks Detected - metal.it
Using Python tools to backtest Akero Therapeutics Inc. strategiesValue Investing Checklist with Entry Signals - Newser
Ranking Akero Therapeutics Inc. among high performing stocks via toolsFree AI Screening for Swing Trade Picks - Newser
Akari Therapeutics Reports Q2 EPS $(0.86) vs. $(0.81) Last Year - AInvest
Why Akero Therapeutics Inc. is moving todaySwing Reversal Forecast Based on Patterns - Newser
Can you recover from losses in Akero Therapeutics Inc.High Probability Trade Plan with Indicators - Newser
Is Akero Therapeutics Inc. building a consolidation baseHigh Reward Investment Strategy for Beginners - Newser
Published on: 2025-08-09 06:15:43 - beatles.ru
Akero Therapeutics Q2 Loss Narrows by 6%, EFX Clinical Trials Progress - AInvest
Vivo Capital LLC Purchases New Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Jefferies Financial Group Inc. Buys New Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
When is the best time to exit Akero Therapeutics Inc.Free AI-Powered Trade Planning with Indicators - Newser
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Rating of "Buy" from Analysts - MarketBeat
Akero Therapeutics Advances in MASH Treatment Development - TipRanks
What MACD and RSI say about Akero Therapeutics Inc.Technical Insight Guide for Safer Trades - Newser
Akero Therapeutics AKRO Q2 2025 Earnings Preview Upside Potential on Efruxifermin Advancements in MASH Treatment - AInvest
Ritu Baral Recommends Buy Rating for Akero Therapeutics Amid Promising Clinical Trials and Strong Financial Position - TipRanks
Akero Therapeutics (NASDAQ:AKRO) Earns Buy Rating from Analysts at TD Cowen - MarketBeat
Akero Therapeutics Keeps Analysts Optimistic Despite Larger Losses - Finimize
Akero Therapeutics shares fall 1.31% intraday after Q2 net loss widens. - AInvest
Akero Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Akero (AKRO) Q2 Loss Narrows 6% - Nasdaq
Akero Therapeutics' Q2 2025 Financial Results and Business Update: A Deep Dive into Metabolic Disease Innovation and Shareholder Value - AInvest
Akero Therapeutics Q2 Net Loss Widens - MarketScreener
Akero Therapeutics, Inc. SEC 10-Q Report - TradingView
Akero Therapeutics Q2 net income just shy of estimates, cash position strong - MarketScreener
Earnings Flash (AKRO) Akero Therapeutics Posts Q2 Net Loss $0.86 a Share, vs. FactSet Est of $0.96 Loss - MarketScreener
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
3 Top Artificial Intelligence (AI) Stocks Ready for a Bull Run - The Globe and Mail
Universal Beteiligungs und Servicegesellschaft mbH Purchases New Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
When is the best time to buy Akero Therapeutics Inc. stockFree Community Shared Smart Money Signals - Newser
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - The Globe and Mail
Insider Selling at Akero Therapeutics: A Cautionary Signal Amidst Promising Clinical Progress - AInvest
Akero therapeutics CSO Rolph sells $616,299 in stock By Investing.com - Investing.com Canada
Allianz Asset Management GmbH Makes New Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics Positioned as Leader in MASH Treatment with Efruxifermin Advancements - TipRanks
Morgan Stanley says zalfermin discontinuation has positive readthrough for Akero - TipRanks
Akero Therapeutics stock strengthened as Morgan Stanley reiterates Overweight rating - Investing.com Canada
TD Cowen Begins Coverage on Akero Therapeutics (NASDAQ:AKRO) - Defense World
Envestnet Asset Management Inc. Buys 3,170 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Akero Therapeutics AKRO Q2 2025 Earnings Preview Upside Potential on Strong Analyst Buy Ratings - AInvest
Akero Therapeutics (AKRO) to Release Earnings on Friday - MarketBeat
TD Cowen Initiates Akero Therapeutics(AKRO.US) With Buy Rating, Announces Target Price $76 - 富途牛牛
Akero Therapeutics stock initiated with Buy rating at TD Cowen on MASH potential - Investing.com Canada
Akero Therapeutics stock initiated with Buy rating at TD Cowen on MASH treatment potential - Investing.com Canada
Analysts Initiate Coverage on Akero Therapeutics, AeroVironment, Wave Life Sciences, Palvella Therapeutics, and WeRide Inc. - AInvest
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Published on: 2025-08-04 16:41:28 - metal.it
These Were the 2 Best-Performing Stocks in the Dow Jones Industrial Average in July 2025 - The Globe and Mail
Akero Therapeutics Inc (AKRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):